Jane Visit 1: Postmenopausal woman with suspected metastatic breast cancer
Curriculum:
N/A
N/A
Credits:
0.5 AMA PRA Category 1 Credit(s)™
0.5 AMA PRA Category 1 Credit(s)™
Launch Date:
17-Dec-09
17-Dec-09
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
No primary audience was provided.
Relevant Terms:
No primary audience was provided.
Monica N. Fornier, MD
Monica N. Fornier, MD
Assistant Professor of Medicine
Breast Cancer Medicine Service
Memorial Sloan-Kettering Cancer Center
New York, New York
Bio
Dr. Monica Fornier is an assistant member of the Breast Cancer Medicine Service at Memorial Sloan-Kettering Cancer Center and specializes in the treatment of breast cancer. She is also an assistant professor at the Weill Cornell Medical College New York-Presbyterian Hospital.
Dr. Fornier graduated summa cum laude from the University of Milan School of Medicine in Italy; she pursued her oncology fellowship at the National Cancer Institute of Milan, under the mentorship of Dr. Gianni Bonadonna, and a second fellowship at Memorial Sloan-Kettering Cancer Center in New York, under the mentorship of Dr. Larry Norton. She is currently a member of the faculty at Memorial Sloan-Kettering Cancer Center, where she conducts clinical research in breast cancer.
Dr. Fornier is an active member of various national and international scientific groups, including the American Society of Clinical Oncology and the European Society of Medical Oncology. Dr. Fornier has numerous publications to her name and has presented data at several international meetings.
Patrick G. Morris, MD, MSc
Patrick G. Morris, MD, MSc
Special Fellow in Breast Medicine
Memorial Sloan-Kettering Cancer Center
New York, New York
Bio
Dr. Patrick Morris graduated summa cum laude from the University College Dublin Faculty of Medicine. In 2007, he was awarded a master of science degree at Trinity College Dublin. He pursued his oncology fellowship at the Royal College of Physicians of Ireland and in 2007 was awarded the Irish Society of Medical Oncology fellowship in advanced hematology and oncology at Memorial Sloan-Kettering Cancer Center. Since that time he has worked under the mentorship of Dr. Clifford Hudis. He has a special interest in the cardiac safety of anthracyclines and novel targeted therapies, including the development of biomarkers to predict toxicity. His other areas of research include the development of new therapies for metastatic breast cancer and the investigation of the pathways involved in metastases through collaborative translational research projects.
| 1. | Interpret results from new and existing HER2 testing methodologies to determine appropriate treatment decisions | 2. | Differentiate between the prognostic and predictive implications associated with HER2 positivity |
| 3. | Compare and contrast monoclonal antibodies and tyrosine kinase inhibitors available for the treatment of HER2-positive breast cancer | 4. | Apply evidence-based clinical trial data on new and emerging treatment strategies to ensure optimal care for patients with HER2-positive breast cancer |
| 5. | Monitor and manage treatment-related toxicities associated with chemotherapeutic and biologic agents used to treat HER2-positive breast cancer |
| 1. | Interpret results from new and existing HER2 testing methodologies to determine appropriate treatment decisions |
| 2. | Differentiate between the prognostic and predictive implications associated with HER2 positivity |
| 3. | Compare and contrast monoclonal antibodies and tyrosine kinase inhibitors available for the treatment of HER2-positive breast cancer |
| 4. | Apply evidence-based clinical trial data on new and emerging treatment strategies to ensure optimal care for patients with HER2-positive breast cancer |
| 5. | Monitor and manage treatment-related toxicities associated with chemotherapeutic and biologic agents used to treat HER2-positive breast cancer |
